Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Annual Review of Pharmacology and Toxicology

• Publication date

  2014-01-06

• Fields of study

  Medicine

• Identifiers
  DOI 10.1146/annurev-pharmtox-011613-135950PMID 24392693PMCID PMC4089991
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The β-catenin destruction complex.

  2013cited by this paper
• The economic burden of treatment-resistant depression.

  2013cited by this paper
• Rapid antidepressant effects of ketamine ignite drug discovery

  2013cited by this paper
• Sub-anesthetic concentrations of (R,S)-ketamine metabolites inhibit acetylcholine-evoked currents in α7 nicotinic acetylcholine receptors.

  2013cited by this paper
• Serial infusions of low-dose ketamine for major depression

  2013cited by this paper
• GSK-3 Inhibition Potentiates the Synaptogenic and Antidepressant-Like Effects of Subthreshold Doses of Ketamine

  2013cited by this paper
• Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.

  2013cited by this paper
• Effects of S-Ketamine as an Anesthetic Adjuvant to Propofol on Treatment Response to Electroconvulsive Therapy in Treatment-Resistant Depression: A Randomized Pilot Study

  2013cited by this paper
• Neural correlates of rapid antidepressant response to ketamine in treatment-resistant unipolar depression: a preliminary positron emission tomography study.

  2013cited by this paper
• Randomized Controlled Crossover Trial of Ketamine in Obsessive-Compulsive Disorder: Proof-of-Concept

  2013cited by this paper
• Human biomarkers of rapid antidepressant effects.

  2013cited by this paper
• Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.

  2013cited by this paper
• Baseline delta sleep ratio predicts acute ketamine mood response in major depressive disorder.

  2013cited by this paper
• Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder.

  2013cited by this paper
• Bayesian model of Hamilton Depression Rating Score (HDRS) with memantine augmentation in bipolar depression.

  2013cited by this paper
• A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression.

  2013cited by this paper
• Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression.

  2012cited by this paper
• Overview of glutamatergic neurotransmission in the nervous system.

  2012cited by this paper
• Ketamine use: a review.

  2012cited by this paper
• mTOR activation is required for the antidepressant effects of mGluR₂/₃ blockade.

  2012cited by this paper
• Lack of effect of ketamine on cortical glutamate and glutamine in healthy volunteers: a proton magnetic resonance spectroscopy study

  2012cited by this paper
• Course of Improvement in Depressive Symptoms to a Single Intravenous Infusion of Ketamine vs Add-on Riluzole: Results from a 4-Week, Double-Blind, Placebo-Controlled Study

  2012cited by this paper
• Compounded oral ketamine.

  2012cited by this paper
• Effects of ketamine in treatment-refractory obsessive-compulsive disorder.

  2012cited by this paper
• The antidepressant-like effects of glutamatergic drugs ketamine and AMPA receptor potentiator LY 451646 are preserved in bdnf⁺/⁻ heterozygous null mice.

  2012cited by this paper
• Family history of alcohol dependence and antidepressant response to an N-methyl-D-aspartate antagonist in bipolar depression.

  2012cited by this paper
• Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.

  2012cited by this paper
• An investigation of amino-acid neurotransmitters as potential predictors of clinical improvement to ketamine in depression.

  2012cited by this paper
• Effects of Propofol and Ketamine as Combined Anesthesia for Electroconvulsive Therapy in Patients With Depressive Disorder

  2012cited by this paper
• Rapid Antidepressant Effect of Ketamine in the Electroconvulsive Therapy Setting

  2012cited by this paper
• Synaptic Dysfunction in Depression: Potential Therapeutic Targets

  2012cited by this paper
• On the safety and benefits of repeated intravenous injections of ketamine for depression.

  2012cited by this paper
• A Randomized, Placebo-Controlled, Crossover Pilot Trial of the Oral Selective NR2B Antagonist MK-0657 in Patients With Treatment-Resistant Major Depressive Disorder

  2012cited by this paper
• Memantine for late‐life depression and apathy after a disabling medical event: a 12‐week, double‐blind placebo‐controlled pilot study

  2012cited by this paper
• Neuropsychological and mood effects of ketamine in electroconvulsive therapy: a randomised controlled trial.

  2012influential reference
• Brain-derived neurotrophic factor Val66Met polymorphism and antidepressant efficacy of ketamine in depressed patients.

  2012cited by this paper
• ¹H-[¹³C]-nuclear magnetic resonance spectroscopy measures of ketamine's effect on amino acid neurotransmitter metabolism.

  2012influential reference
• Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression.

  2012cited by this paper
• Mood and Pain Responses to Repeat Dose Intramuscular Ketamine in a Depressed Patient with Advanced Cancer

  2012cited by this paper
• Long-term maintenance with intramuscular ketamine for treatment-resistant bipolar II depression.

  2012cited by this paper
• Early antidepressant effect of memantine during augmentation of lamotrigine inadequate response in bipolar depression: a double‐blind, randomized, placebo‐controlled trial

  2012cited by this paper
• NMDA receptor function in large-scale anticorrelated neural systems with implications for cognition and schizophrenia

  2012cited by this paper
• Signaling pathways underlying the rapid antidepressant actions of ketamine.

  2012cited by this paper
• Inhibition of glycogen synthase kinase-3 attenuates psychotomimetic effects of ketamine.

  2012cited by this paper
• Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex.

  2012cited by this paper
• Possible antidepressant effects and mechanisms of memantine in behaviors and synaptic plasticity of a depression rat model.

  2011cited by this paper
• The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS.

  2011cited by this paper
• NMDA Receptor Blockade at Rest Triggers Rapid Behavioural Antidepressant Responses

  2011influential reference
• Author ' s personal copy POSSIBLE ANTIDEPRESSANT EFFECTS AND MECHANISMS OF MEMANTINE IN BEHAVIORS AND SYNAPTIC PLASTICITY OF A DEPRESSION RAT MODEL

  2011cited by this paper
• The brain-derived neurotrophic factor is associated with alcohol dependence-related depression and antidepressant response.

  2011cited by this paper
• Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure.

  2011influential reference
• Reduced dorsal prefrontal gray matter after chronic ketamine use.

  2011cited by this paper
• Permanent deficits in brain functions caused by long-term ketamine treatment in mice

  2011cited by this paper
• Clinically favourable effects of ketamine as an anaesthetic for electroconvulsive therapy: a retrospective study

  2011cited by this paper
• A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department.

  2011cited by this paper
• Clinical practice. Bipolar disorder--a focus on depression.

  2011influential reference
• A case of sustained remission following an acute course of ketamine in treatment-resistant depression.

  2011cited by this paper
• Ketamine Activates the l-Arginine/Nitric Oxide/Cyclic Guanosine Monophosphate Pathway to Induce Peripheral Antinociception in Rats

  2011cited by this paper
• Bipolar disorder--a focus on depression.

  2011cited by this paper
• Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression.

  2011cited by this paper
• Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study.

  2011cited by this paper
• Monitoring ketamine treatment response in a depressed patient via peripheral mammalian target of rapamycin activation.

  2011cited by this paper
• Psychiatric Stress Testing: Novel Strategy for Translational Psychopharmacology

  2010cited by this paper
• Consistency and change in club drug use by sexual minority men in New York City, 2002 to 2007.

  2010cited by this paper
• Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders.

  2010cited by this paper
• Antidepressant-like effects of an AMPA receptor potentiator under a chronic mild stress paradigm.

  2010cited by this paper
• NMDA receptor antagonists augment antidepressant-like effects of lithium in the mouse forced swimming test

  2010cited by this paper
• Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.

  2010cited by this paper
• Taming the Ketamine Tiger

  2010cited by this paper
• mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists

  2010influential reference
• Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.

  2010cited by this paper
• A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.

  2010cited by this paper
• Rapid Antidepressant Effect of Ketamine Anesthesia During Electroconvulsive Therapy of Treatment-Resistant Depression: Comparing Ketamine and Propofol Anesthesia

  2010cited by this paper
• The use of a series of ketamine infusions in two patients with treatment-resistant depression.

  2010cited by this paper
• Oral Ketamine for the Rapid Treatment of Depression and Anxiety in Patients Receiving Hospice Care

  2010cited by this paper
• Emergency department presentation of ketamine abusers in Hong Kong: a review of 233 cases.

  2010cited by this paper
• Neurochemical and behavioural effects of acute and chronic memantine administration in rats: Further support for NMDA as a new pharmacological target for the treatment of depression?

  2010cited by this paper
• Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study.

  2010cited by this paper
• Frontal white matter abnormalities following chronic ketamine use: a diffusion tensor imaging study.

  2010cited by this paper
• Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial.

  2010cited by this paper
• Anterior Cingulate Desynchronization and Functional Connectivity with the Amygdala During a Working Memory Task Predict Rapid Antidepressant Response to Ketamine

  2010cited by this paper
• Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist.

  2009cited by this paper
• Neuropeptide and Sigma Receptors as Novel Therapeutic Targets for the Pharmacotherapy of Depression

  2009cited by this paper
• Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression.

  2009cited by this paper
• The STAR*D trial: revealing the need for better treatments.

  2009cited by this paper
• Repeated intravenous ketamine therapy in a patient with treatment-resistant major depression

  2009cited by this paper
• Effects of the Brain-Derived Neurotrophic Growth Factor Val66Met Variation on Hippocampus Morphology in Bipolar Disorder

  2009cited by this paper
• Use of ecstasy and other psychoactive substances among school-attending adolescents in Taiwan: national surveys 2004–2006

  2009cited by this paper
• Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine.

  2009cited by this paper
• Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist.

  2009cited by this paper
• Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials.

  2009cited by this paper
• Ketamine followed by memantine for the treatment of major depression.

  2008cited by this paper
• Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence.

  2008cited by this paper
• Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder.

  2008cited by this paper
• Differential effects of citalopram and reboxetine on cortical Glx measured with proton MR spectroscopy

  2008cited by this paper
• Substance Abuse Treatment, Prevention, and Policy Treatment of Alcohol Dependence in Patients with Co-morbid Major Depressive Disorder – Predictors for the Outcomes with Memantine and Escitalopram Medication

  2008cited by this paper
• Increased response to ketamine following treatment at long intervals: implications for intermittent use.

  2008cited by this paper
• An Innovative Design to Establish Proof of Concept of the Antidepressant Effects of the NR2B Subunit Selective N-Methyl-D-Aspartate Antagonist, CP-101,606, in Patients With Treatment-Refractory Major Depressive Disorder

  2008cited by this paper
• Ketamine exposure in adult mice leads to increased cell death in C3H, DBA2 and FVB inbred mouse strains.

  2008cited by this paper
• Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors.

  2008cited by this paper

• The Emerging Crisis in Non-Prescribed Ketamine Use: A Rapid Attenuation of Depression in Face of Abuse and "Chill-out" or Escapism Drug.

  2026cites this paper
• New advances in small molecule drugs targeting NMDA receptors

  2025cites this paper
• New insights into the molecular pathophysiology and treatment of depression.

  2025cites this paper
• Mechanistic intersections between migraine and major depressive disorder

  2025influential citation
• Network localization of functional brain changes associated with ketamine's therapeutic effects in depression.

  2025cites this paper
• Xenon gas as a potential treatment for opioid use disorder, alcohol use disorder, and related disorders

  2025cites this paper
• Spectral signatures of psilocybin, lysergic acid diethylamide (LSD) and ketamine in healthy volunteers and persons with major depressive disorder and treatment-resistant depression: A systematic review.

  2024cites this paper
• Mechanistic insights into behavioral clusters associated with cancer-related systemic inflammatory response

  2024cites this paper
• Ketamine modulates the exploratory dynamics and homebase-related behaviors of adult zebrafish.

  2024cites this paper
• Neurobiological mechanisms in the kynurenine pathway and major depressive disorder

  2024cites this paper
• The anti-anhedonic effects of ketamine in the treatment of resistant unipolar and bipolar depression: A systematic review and meta-analysis of current data

  2024cites this paper
• A Novel Analog of the Natural Product Fraxinellone Protects against Endogenous and Exogenous Neurotoxicants

  2024cites this paper
• Neuroprotective effects of Shaoyao Gancao decoction against excitatory damage in PC12 cells based on the Src-NR2-nNOS pathway

  2024cites this paper
• Structural insights into NMDA receptor pharmacology

  2023cites this paper
• Herbal Interventions as Promising Therapeutics for Alleviating of Depression

  2023cites this paper
• The SLC6A15–SLC6A20 Neutral Amino Acid Transporter Subfamily: Functions, Diseases, and Their Therapeutic Relevance

  2023cites this paper
• Single subanesthetic dose of ketamine produces delayed impact on brain [18F]FDG PET imaging and metabolic connectivity in rats

  2023cites this paper
• Predicting efficacy of sub-anesthetic ketamine/esketamine i.v. dose during course of cesarean section for PPD prevention, utilizing traditional logistic regression and machine learning models.

  2023cites this paper
• Therapeutic potential of N-methyl-D-aspartate receptor modulators in psychiatry

  2023cites this paper
• Auditory brainstem responses are resistant to pharmacological modulation in Sprague Dawley wild-type and Neurexin1α knockout rats

  2023cites this paper
• Pharmacological evidence for glutamatergic pathway involvement in the antidepressant-like effects of 2-phenyl-3-(phenylselanyl)benzofuran in male Swiss mice

  2023cites this paper
• The potential of ketamine for posttraumatic stress disorder: a review of clinical evidence

  2023cites this paper
• Pterosin sesquiterpenoids from Pteris laeta Wall. ex Ettingsh. Protect cells from glutamate excitotoxicity by modulating mitochondrial signals.

  2023cites this paper
• Brain function changes reveal rapid antidepressant effects of nitrous oxide for treatment-resistant depression:Evidence from task-state EEG.

  2023cites this paper
• Memantine for Refractory Obsessive-Compulsive Disorder: Protocol for a Pragmatic, Double-blind, Randomized, Parallel-Group, Placebo-Controlled, Monocenter Trial

  2022cites this paper
• Efficacy and safety of Gyejibokryeong-hwan (GBH) in major depressive disorder: study protocol for multicentre randomised controlled trial

  2022cites this paper
• Neural Plasticity in the Ventral Tegmental Area, Aversive Motivation during Drug Withdrawal and Hallucinogenic Therapy

  2022influential citation
• Association between peripheral inflammation and free-water imaging in Major Depressive Disorder before and after ketamine treatment - A pilot study.

  2022cites this paper
• Antiglutamatergic agents for obsessive-compulsive disorder: Where are we now and what are possible future prospects?

  2021cites this paper
• Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder.

  2021cites this paper
• Neuronal Nsun2 deficiency produces tRNA epitranscriptomic alterations and proteomic shifts impacting synaptic signaling and behavior

  2021cites this paper
• Oligonucleotides as therapeutic tools for brain disorders: Focus on major depressive disorder and Parkinson's disease.

  2021cites this paper
• Nitrous oxide as an adjunctive therapy in major depressive disorder: a randomized controlled double-blind pilot trial

  2021cites this paper
• Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status

  2021cites this paper
• Neuronal Nsun2 deficiency produces tRNA epitranscriptomic alterations and proteomic shifts impacting synaptic signaling and behavior

  2021cites this paper
• Ketamine Sedation Facilitates Asleep DBS: a multicenter retrospective study

  2021cites this paper
• Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels

  2021cites this paper
• Extending the Specificity of DRL 72-s Behavior for Screening Antidepressant-Like Effects of Glutamatergic Clinically Validated Anxiolytic or Antidepressant Drugs in Rats

  2020cites this paper
• PTC-174, a positive allosteric modulator of NMDA receptors containing GluN2C or GluN2D subunits.

  2020cites this paper
• 'That's the Esketamine, Baby, there's Nothing You Can Do about It!' An Update on Glutamatergic System in Suicidal Depression.

  2020cites this paper
• Acute changes in cerebral blood flow after single-infusion ketamine in major depression: a pilot study.

  2020cites this paper
• Breaking Away: The Role of Homeostatic Drive in Perpetuating Depression

  2020cites this paper
• I. Antidepressants and sexual behavior: Weekly ketamine injections increased sexual behavior initially in female and male rats.

  2020cites this paper
• Ketamine Sensitization: Influence of Dose, Environment, Social Isolation and Treatment Interval.

  2020cites this paper
• Rapastinel, an NMDAR Positive Modulator, Produces Distinct Behavioral, Sleep, and EEG Profiles Compared with Ketamine.

  2020cites this paper
• Ketamine’s pharmacogenomic network in human brain contains sub-networks associated with glutamate neurotransmission and with neuroplasticity

  2020cites this paper
• A Review of Nonanesthetic Uses of Ketamine

  2020cites this paper
• NMDA Antagonists and Their Role in the Management of Bipolar Disorder: a Review

  2020cites this paper
• Rapid Anti-Depressant Relief by Ketamine: Exploring A Complex Mechanism of Action

  2019cites this paper
• L‐alpha‐amino adipic acid provokes depression‐like behaviour and a stress related increase in dendritic spine density in the pre‐limbic cortex and hippocampus in rodents

  2019cites this paper
• Novel Therapeutic Targets for Major Depressive Disorder

  2019cites this paper
• Molecular, Cellular, and Circuit Basis of Depression Susceptibility and Resilience

  2019cites this paper
• Increased Fear Memory and Glutamatergic Modulation in Compulsive Drinker Rats Selected by Schedule-Induced Polydipsia

  2019cites this paper
• Pharmacological Treatments for Obsessive-Compulsive and Related Disorders: A Transdiagnostic Perspective

  2019cites this paper
• Neural mechanisms underlying adaptive and maladaptive consequences of stress: Roles of dopaminergic and inflammatory responses

  2019cites this paper
• The faster-onset antidepressant effects of hypidone hydrochloride (YL-0919)

  2019cites this paper
• Journal of Clinical Anesthesia and Pain Management

  2019cites this paper
• The Role of N-methyl-D-aspartate Receptor on Late-Life Depression

  2019cites this paper
• Does oral administration of ketamine accelerate response to treatment in major depressive disorder? Results of a double-blind controlled trial.

  2018cites this paper
• Molecular and cellular dissection of NMDA receptor subtypes as antidepressant targets

  2018cites this paper
• Glutamatergic Modulators in Depression

  2018cites this paper
• Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial

  2018cites this paper
• IV Ketamine Infusions for the Treatment of Depression: An Evidence Based Practice Analysis

  2018cites this paper
• Antidepressant Efficacy and Tolerability of Ketamine and Esketamine: A Critical Review

  2018cites this paper
• Ketamine Anesthesia Does Not Improve Depression Scores in Electroconvulsive Therapy: A Randomized Clinical Trial

  2018cites this paper
• S-Ketamine Mediates Its Acute and Sustained Antidepressant-Like Activity through a 5-HT1B Receptor Dependent Mechanism in a Genetic Rat Model of Depression

  2018cites this paper
• Breaking Away: The Role of Homeostatic Drive in Perpetuating Depression.

  2018cites this paper
• The Hippocampus is a Critical Site Mediating Antidepressant-like Activity of Apelin-13 in Rats.

  2018cites this paper
• Depression in type 1 diabetes was associated with high levels of circulating galectin-3

  2018cites this paper
• The Epigenetics of Early Life Adversity: Current Limitations and Possible Solutions.

  2018cites this paper
• Segregating polymorphism in the NMDA receptor gene GRIN2A, schizotypy, and mental rotation among healthy individuals

  2018cites this paper
• What Acute Stress Protocols Can Tell Us About PTSD and Stress-Related Neuropsychiatric Disorders

  2018cites this paper
• Structure, function, and allosteric modulation of NMDA receptors

  2018cites this paper
• Differences in excitatory and inhibitory neurotransmitter levels between depressed patients and healthy controls: A systematic review and meta-analysis.

  2018cites this paper
• 1,2-Diarylethylamine- and Ketamine-Based New Psychoactive Substances.

  2018cites this paper
• Mechanism underlying NMDA blockade‐induced inhibition of aggression in post‐weaning socially isolated mice

  2018cites this paper
• Diminished responses to monoaminergic antidepressants but not ketamine in a mouse model for neuropsychiatric lupus

  2018cites this paper
• Positive N-Methyl-D-Aspartate Receptor Modulation by Rapastinel Promotes Rapid and Sustained Antidepressant-Like Effects

  2018cites this paper
• New Role of Ketamine for Reversing the Unrelenting Treatment-Resistant Major Depression

  2017cites this paper
• A single administration of the hallucinogen, 4‐acetoxy‐dimethyltryptamine, prevents the shift to a drug‐dependent state and the expression of withdrawal aversions in rodents

  2017cites this paper
• The effect of ketamine on microglia and proinflammatory cytokines in the hippocampus of depression-like rat

  2017cites this paper
• Acute stress regulates phosphorylation of N-methyl-d-aspartate receptor GluN2B at S1284 in hippocampus.

  2017cites this paper
• New targets for rapid antidepressant action.

  2017cites this paper
• Cortical Astroglial Plasticity in Response to Stress and Antidepressant Treatment

  2017cites this paper
• Ketamine-based Treatment of MDD: A Biologist’s Perspective

  2017cites this paper
• Advances in discovering the interrelationship between mental disorders and heart diseases

  2017cites this paper
• Use of Ketamine in Clinical Practice: A Time for Optimism and Caution.

  2017cites this paper
• Up‐regulation of insulin‐like growth factor 2 by ketamine requires glycogen synthase kinase‐3 inhibition

  2017cites this paper
• Using the research domain criteria (RDoC) to conceptualize impulsivity and compulsivity in relation to addiction.

  2017cites this paper
• NMDA receptors: linking physiological output to biophysical operation

  2017cites this paper
• Ketamine up-regulates a cluster of intronic miRNAs within the serotonin receptor 2C gene by inhibiting glycogen synthase kinase-3

  2017cites this paper
• NMDA Receptors in the Central Nervous System.

  2017cites this paper
• Increasing Ketamine Use for Refractory Status Epilepticus in US Pediatric Hospitals

  2017influential citation
• Prefrontal Connectivity and Glutamate Transmission: Relevance to Depression Pathophysiology and Ketamine Treatment.

  2017cites this paper
• Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion.

  2017influential citation
• Neural Substrates of Depression and Resilience

  2017cites this paper
• Efficacy and safety of ketamine in bipolar depression: A systematic review.

  2017cites this paper
• Glutamate-Modulating Drugs as a Potential Therapeutic Strategy in Obsessive-Compulsive Disorder

  2017cites this paper
• New Treatment Strategies of Depression: Based on Mechanisms Related to Neuroplasticity

  2017influential citation
• Efficacy and safety of ketamine in bipolar depression: A systematic review.

  2017cites this paper